Artoss

Artoss is a commercial-stage orthobiologics company with its core product, NanoBone, already approved and used in over 100,000 surgical cases in the U.S. and EU. The company's technology is centered on a unique nanocrystalline hydroxyapatite embedded in an amorphous silica gel matrix (ASG), which is rapidly replaced by the patient's own organic bone matrix. Led by a seasoned executive team with deep experience in medical device sales and orthobiologics, Artoss is targeting the large and growing bone graft substitute market by positioning NanoBone as a cost-effective, easy-to-use, and clinically effective alternative to autograft and more expensive biologics. The company is actively gathering real-world clinical data through several patient registries to further validate and expand the use of its product.

Synthetic bone graft substitute composed of nanocrystalline hydroxyapatite embedded in a bioreactive amorphous silica gel (ASG) matrix. The ASG is designed to be rapidly replaced by the patient's own organic bone matrix within 14 days, creating a native osteogenic scaffold.

Artoss competes in the synthetic bone graft segment against major players like Medtronic (Infuse, Mastergraft), Stryker (Vitoss), Zimmer Biomet (CopiOs), and a range of ceramic and polymer-based products. Its key differentiators are its nanotechnology platform, rapid matrix conversion claim, and putty-like handling. It positions itself as a mid-tier option: more advanced and effective than basic ceramics, but more affordable and predictable than high-cost growth factor (BMP) or cell-based therapies.